In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall ...
The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.
Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...
Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Patients and Methods: A total of 320 patients with AOC were centrally screened for HER2 status (243 patients in fi rst line, 77 in relapse). All positive (IHC 3+) and doubtful (IHC 2+) cases were ...
Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.
It’s natural to worry that your HER2-positive breast cancer might spread. Learn why this can happen and what signs to watch for.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback